Polyrizon Secures $17M Funding Amid Nasdaq Compliance Issues
By ATTN Desk · Editorial oversight: Sean Han
Polyrizon Ltd (NASDAQ: PLRZ)
Introduction
Polyrizon Ltd is a development-stage biotechnology company specializing in intranasal medical device hydrogels. Its proprietary Capture & Contain™ (C&C) hydrogel is delivered via nasal spray to form a barrier against viruses and allergens on the nasal epithelium. The company is also advancing its Trap & Target™ (T&T) platform for intranasal delivery of active pharmaceutical ingredients (APIs).
| Metric | Value |
|---|---|
| Ticker | PLRZ |
| Exchange | NAS |
| Price (2025-05-28) | $0.8198 |
| Daily Change | +26.90% |
| Volume | 713,333 |
| 52-Week Range | $0.55 – $1.20 |
| Average Volume (10 days) | 359,274 |
| Market Cap (intraday) | $2.25 M |
Corporate Structure
- Headquarters: Raanana, Israel
- Founded: 2005
- Employees: 2 – 10 (LinkedIn)
Leadership Team
- Tomer Izraeli, Founder & Chief Executive Officer (B.Sc, MBA)
- Nir Ben Yosef, Chief Financial Officer (CPA, B.A)
- Daphna Avital, Chief People Officer (M.A)
- Dr. Eyal S. Ron, Chief Scientific Officer
- Dr. Tidhar Turgeman, Chief Technology Officer
- Asaf Azulay, VP Regulatory Affairs & Quality Assurance
- Sapir Abraham, Director of Regulatory Affairs & QA
Board of Directors
- Tomer Izraeli
- Asaf Itzhaik
- Omer Srugo
- Liat Sidi
- Yehonatan Zalman Vinokur
- Oz Adler
Developments and News
- 2025-04-01: Closed a $17.0 M private placement of 35,416,667 Ordinary Units at $0.48 per unit. Each unit included one Ordinary Share (or pre-funded warrant) and one Series A warrant exercisable at $1.20 for 30 months.
- 2025-05-01: Announced a 1-for-10 reverse share split effective May 5, 2025; later that day the company canceled the split.
- 2025-05-02: Following the split cancellation, shares increased to $0.82.
- 2025-05-21: Filed Form 6-K disclosing preclinical data related to its nasal protection platform.
- 2025-05-23: Filed Form 6-K reporting receipt of a Nasdaq delisting notice; details to be included in a forthcoming Form S-8 registration statement.
Financial and Strategic Analysis
Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $2.25 M |
| Enterprise Value | $2.84 M |
| Net Income (TTM) | –$1.6 M |
| Diluted EPS (TTM) | –125.00 |
| Total Cash (MRQ) | $2.55 M |
| Levered Free Cash Flow | –$771.8 K |
| Price/Book (MRQ) | 0.43 |
- Cash Runway: As of the latest filings, the company indicated it has sufficient capital to fund operations for approximately 40 months.
- Use of Proceeds: Net proceeds from the April 1 placement are expected to support general corporate and working capital needs.
- Strategic Focus: The focus remains on the advancement of C&C hydrogel for barrier protection and progress on T&T API delivery.
Market Position and Industry Context
- Sector: Biotechnology – medical device hydrogels and drug delivery.
- Development Stage: The company has not generated product revenues and relies on financing and R&D progress.
- Share Liquidity: Average trading volume is approximately 359,000 shares, with noted volatility around corporate actions.
- Exchange Listing: The company is listed on the Nasdaq Capital Market; the receipt of a delisting notice is a compliance concern.
- Competitive Landscape: The company operates in the market of intranasal delivery systems and hydrogels, facing competition from others developing similar therapeutic products.
tl;dr
- On April 1, 2025, Polyrizon raised $17 M through a private placement at $0.48 per unit, which includes warrants exercisable at $1.20.
- A planned 1-for-10 reverse split was announced on May 1 and subsequently canceled the same day, leading to an increase in share price.
- A Form 6-K filing on May 21 disclosed positive preclinical data; on May 23, the company reported receiving a Nasdaq delisting notice.
- As of the last update, cash reserves support approximately 40 months of continued operations, and management is expected to address compliance with Nasdaq regulations while advancing R&D initiatives.